In 2023, around 72,776 people in the United States died from a drug overdose that involved fentanyl. This was the second-highest number of fentanyl overdose deaths ever recorded in the United States, and a significant increase from the number of deaths reported in 2019. Fentanyl overdoses are now the driving force behind the opioid epidemic, accounting for the majority of overdose deaths in the United States. What is fentanyl? Fentanyl is an extremely potent synthetic opioid similar to morphine, but more powerful. It is a prescription drug but is also manufactured illegally and is sometimes mixed with other illicit drugs such as heroin and cocaine, often without the user’s knowledge. The potency of fentanyl makes it very addictive and puts users at a high risk for overdose. Illegally manufactured fentanyl has become more prevalent in the United States in recent years, leading to a huge increase in drug overdose deaths. In 2022, the rate of drug overdose death involving fentanyl was 22.7 per 100,000 population, compared to a rate of just one per 100,000 population in the year 2013. Fentanyl overdoses by gender and race/ethnicity As of 2022, the rate of drug overdose deaths involving fentanyl in the United States is over two times higher among men than women. Rates of overdose death involving fentanyl were low for both men and women until around the year 2014 when they began to quickly increase, especially for men. In 2022, there were around 19,880 drug overdose deaths among women that involved fentanyl compared to 53,958 such deaths among men. At that time, the rate of fentanyl overdose deaths was highest among non-Hispanic American Indian or Alaska Natives and lowest among non-Hispanic Asians. However, from the years 2014 to 2018, non-Hispanic whites had the highest fentanyl overdose death rates.

The graph illustrates the number of deaths from fentanyl in the United States from 1999 to 2022. The x-axis represents the years, spanning from '99 to '22, while the y-axis displays the annual number of fentanyl-related fatalities. Over this 24-year period, deaths rise dramatically from 730 in 1999 to a peak of 73,838 in 2022. Notable milestones include an increase to 1,742 deaths in 2005, a significant jump to 9,580 in 2015, and a sharp escalation to 70,601 deaths by 2021. The data reveals a consistent and severe upward trend in fentanyl-related deaths, particularly accelerating in the mid-2010s. This information is presented in a line graph format, effectively highlighting the dramatic increase in fatalities due to fentanyl across the United States over the specified years.

In 2023, the death rate from opioid overdose was ** per 100,000 population. Opioids are the main driver of overdose deaths in the United States. This statistic presents the death rate from opioid overdose in the U.S. from 1999 to 2023, per 100,000 population.

In 2022, there were around ** overdose deaths involving fentanyl among non-Hispanic whites in the United States per 100,000 population. This statistic presents the rate of drug overdose deaths involving fentanyl in the U.S. from 1999 to 2022, by race/ethnicity.

The graph displays the number of drug overdose deaths in the U.S. from 2003 to 2023, with the x-axis representing the years and the y-axis showing the total overdose deaths each year. The data reveals a steady increase in deaths from 25,785 in 2003 to over 107,000 in 2022, highlighting the growing severity of the overdose crisis. The highest number of deaths occurred in 2022 (107,941), while 2023 saw a slight decrease to 105,007 deaths. A sharp rise is observed between 2015 and 2021, coinciding with the opioid epidemic and increased fentanyl-related overdoses. The data underscores the urgent need for stronger prevention and intervention efforts.

This data visualization presents county-level provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. County-level provisional counts include deaths occurring within the 50 states and the District of Columbia, as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts (see Technical Notes). The provisional data presented on the dashboard below include reported 12 month-ending provisional counts of death due to drug overdose by the decedent’s county of residence and the month in which death occurred. Percentages of deaths with a cause of death pending further investigation and a note on historical completeness (e.g. if the percent completeness was under 90% after 6 months) are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts (see Technical Notes). Counts between 1-9 are suppressed in accordance with NCHS confidentiality standards. Provisional data presented on this page will be updated on a quarterly basis as additional records are received. Technical Notes Nature and Sources of Data Provisional drug overdose death counts are based on death records received and processed by the National Center for Health Statistics (NCHS) as of a specified cutoff date. The cutoff date is generally the first Sunday of each month. National provisional estimates include deaths occurring within the 50 states and the District of Columbia. NCHS receives the death records from the state vital registration offices through the Vital Statistics Cooperative Program (VSCP). The timeliness of provisional mortality surveillance data in the National Vital Statistics System (NVSS) database varies by cause of death and jurisdiction in which the death occurred. The lag time (i.e., the time between when the death occurred and when the data are available for analysis) is longer for drug overdose deaths compared with other causes of death due to the time often needed to investigate these deaths (1). Thus, provisional estimates of drug overdose deaths are reported 6 months after the date of death. Provisional death counts presented in this data visualization are for “12 month-ending periods,” defined as the number of deaths occurring in the 12 month period ending in the month indicated. For example, the 12 month-ending period in June 2020 would include deaths occurring from July 1, 2019 through June 30, 2020. The 12 month-ending period counts include all seasons of the year and are insensitive to reporting variations by seasonality. These provisional counts of drug overdose deaths and related data quality metrics are provided for public health surveillance and monitoring of emerging trends. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12 month-ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Cause of Death Classification and Definition of Drug Deaths Mortality statistics are compiled in accordance with the World Health Organizations (WHO) regulations specifying that WHO member nations classify and code causes of death with the current revision of the International Statistical Classification of Diseases and Related Health Problems (ICD). ICD provides the basic guidance used in virtually all countries to code and classify causes of death. It provides not only disease, injury, and poisoning categories but also the rules used to select the single underlying cause of death for tabulation from the several diagnoses that may be reported on a single death certificate, as well as definitions, tabulation lists, the format of the death certificate, and regul

From 1999 to 2023, the number of drug overdose deaths among U.S. females increased from ***** in 1999 to ****** in 2023. Globally, drug use is a general problem. As of 2021, there were an estimated *** million global drug consumers and **** million drug addicts. Opioid use in the United States Among many demographics, drug overdose deaths continue to rise in the United States. Opioids are the most commonly reported substance in drug-related deaths. The number of drug-related deaths in the U.S. due to opioids has dramatically increased since the early 2000s. In 2017, then-President Donald Trump declared a national emergency over the opioid crisis in the United States. Since then, there have been joint efforts among various governmental departments to address the opioid crisis through education and outreach. Substance use treatment Substance abuse treatment is vital in reducing the number of drug overdose deaths in the United States. As of 2020, the state of California had the largest number of substance abuse treatment facilities . However, many states in the U.S. have less than 100 substance abuse treatment facilities.

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

We collect data and report statistics on opioid, stimulant, and other substance use and their impact on health and well-being.

In 2023, there were a total of 8,606 deaths in Canada due to opioid overdose, with around 82 percent of these deaths involving fentanyl. This statistic shows the share of deaths from opioid overdose in Canada from 2016 to 2023 that involved select drugs.

This data presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts. Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts. Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made. Provisional data presented will be updated on a monthly basis as additional records are received. For more information please visit: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

In 2022, there were around 22.7 overdose deaths in the United States involving fentanyl per 100,000 population. The death rate involving fentanyl presented an exponential increase since 2014. This statistic presents the rate of drug overdose deaths involving fentanyl in the U.S. from 1999 to 2022.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

In 2022, those aged between 35 and 44 years had the highest number of drug overdose deaths in the United States, with 27,583 deaths. Opioids are the main driver of overdose deaths in the United States. This statistic presents the number of drug overdose deaths in the U.S. from 2013 to 2022, by age group.

Life expectancy at birth, at the health region level, is decomposed by drug overdose deaths. Changes in mortality rates for a given cause of death change over time and contribute to the overall change in life expectancy.

Annual number of deaths registered related to drug poisoning, by local authority, England and Wales.

In 2022, Ireland had the highest incidence of drug-induced deaths in Europe at ** per million population. This was followed by Estonia at ** deaths per million population, and ** deaths per million in Norway. On the other hand, in Romania, there were only * drug-induced deaths per million population in 2022. Number of drug-induced deaths There were nearly *** thousand drug-related deaths reported in the EU in 2022. There was a steady increase in the number of deaths in the EU from only *** thousand cases in 2013. When combined with Turkey and Norway, the number of drug-induced deaths in 2022 nearly reached ***** thousand. This was the highest number of drug-related deaths recorded in the given period. Drug deaths by gender and age In 2022, 77 percent of drug-induced deaths reported in the EU were attributed to men. Half of the deaths that occurred among men were among those aged between 25 and 44 years. Similarly, the largest share of female deaths due to drug use was also reported in the same age group.

In 2023, there were a total of 5,975 deaths in Canada due to opioid overdose, with around 30 percent of deaths occurring among those aged 30 to 39 years. This statistic shows the distribution of deaths from opioid overdose in Canada from 2016 to 2023, by age.

Snapshot img

What is the Size of Opioid Rescue Products Market?

The opioid rescue products market size is forecast to increase by USD 1.69 billion, at a CAGR of 11.6% between 2023 and 2028. The market is experiencing significant growth due to the escalating opioid overdose crisis in the US. According to the National Institute on Drug Abuse, over 130 Americans die daily from an opioid overdose. In response, the opioid industry is focusing on the development and approval of new drugs to address this public health concern. For instance, sublingual tablets and transdermal patches are gaining popularity as they offer quicker relief and improved treatment access for patients suffering from opioid overdoses. However, challenges persist, including the presence of counterfeit drugs and the management of comorbid illnesses such as constipation, which are common in opioid users. The approval of new drugs and the continued innovation in delivery systems will be crucial in addressing these challenges and reducing opioid-related deaths.

Request Free Opioid Rescue Products Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Distribution Channel

  Offline
  Online


Product Type

  Naloxone
  Naltrexone
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France
    Spain


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

Which is the Largest Segment Driving Market Growth?

The offline segment is estimated to witness significant growth during the forecast period. Opioid rescue products, such as naloxone and naltrexone, play a crucial role in reversing the effects of opioid overdoses and treating opioid addiction. Pharmacies serve as essential distribution channels for these medications, making them easily accessible to the public. Prescriptions and, in certain cases, over-the-counter sales are options for obtaining these life-saving drugs.

Get a glance at the market share of various regions Download the PDF Sample

The offline segment was valued at USD 896.70 million in 2018. Major pharmacy chains significantly contribute to making opioid rescue products readily available. First responders, including paramedics, police officers, emergency medical technicians, and non-emergency medical personnel, are increasingly utilizing opioid rescue products. These professionals are often the first on the scene during an opioid overdose and can administer immediate intervention, which is vital in preventing fatalities. Non-governmental organizations also play a significant role in increasing awareness and providing training on the use of opioid rescue products to first responders and the general public.

Which Region is Leading the Market?

For more insights on the market share of various regions Request Free Sample

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The opioid crisis is a major public health concern in North America, affecting both the United States and Canada. In the United States, during the 12 months ending in February 2023, over 105,000 reported opioid overdoses occurred, primarily due to synthetic opioids like illicit fentanyl. This startling figure highlights the importance of having effective opioid rescue products available to counteract the potentially fatal consequences of opioid overdoses. In Canada, the opioid overdose crisis continues to pose a significant threat to individuals, families, and communities. This crisis is considered one of the most severe public health crises in the country's recent history. Between January 2016 and June 2022, there were approximately 32,600 apparent opioid toxicity deaths. Opioid overdoses can lead to respiratory depression and psychological problems, making it crucial to have accessible and efficient opioid rescue products.

Opioid rescue products, such as naloxone and buprenorphine, play a vital role in reversing opioid overdoses. These medications can help restore normal breathing and prevent further harm. The ongoing opioid crisis necessitates the continuous development and availability of these essential treatments. In conclusion, the opioid crisis is a pressing issue in North America, with the US and Canada experiencing high numbers of opioid overdoses and fatalities. Effective opioid rescue products, like naloxone and buprenorphine, are essential in mitigating the devastating effects of opioid overdoses. It is crucial to ensure these treatments are accessible and readily available to those in need.

How do Technavio's company ranking index

The United States is battling an opioid overdose epidemic, and Veterans are at almost double the risk compared to the general population. Veterans Health Administration (VHA) recognizes the critical role naloxone plays as a risk mitigation strategy in opioid prescribing; however, there was not a standardized process within the Kansas City VA Medical Center’s (KCVAMC) community care program. This quality improvement project included Veterans that received opioids through community care from 2022 to 2023. The Stratification Tool for Opioid Risk Mitigation and chart review were used along with descriptive statistics. Results found 11% (22 of 206) of Veterans were dispensed naloxone within one year prior to receiving their opioid prescription. This data indicated the importance of expanding access to naloxone in Veterans receiving opioids from community care providers. As a result of this data, the KCVAMC implemented an outpatient pharmacy protocol to dispense naloxone to appropriate Veterans that receive an opioid through the community care program. The protocol was initiated on March 29, 2023. From the end of March through 2023, naloxone dispensing for these Veterans increased from 11% to 67%.